Abstract
Background: Study of drug utilization and expenditure patterns is an important tool of the health system. A void exists in such research in sub-Saharan Africa. This is a pilot study on the drug expenditure and utilization patterns in an ideal community pharmacy in south-western Nigeria.
Methods: Data on drug expenditure (NGN) and drug quantity (mg) for cardiovascular and anti-infective drugs were obtained from the electronic database of the pharmacy over a period of twenty-two months. Data analysed within the period included 63,157 items.
Results: The total drug utilization, 50.82 kg and expenditure, NGN 30,908,084.10 ($190,790.64) for cardiovascular and anti-infective drugs within the study period comprised NGN 22,761,195.88 ($140,501.21) for anti-infectives (73.64%) and the remaining ¦ 8,146,888.22 ($50,289.43) for cardiovascular drugs (26.36%). Anti-infective drugs utilization was more, 48.14 kg (94.73%) compared to cardiovascular drugs, 2.68kg (5.27%) p<0.05. Antimalarial drugs utilization 2,253,000 mg at NGN 2,276, 255 ($14,050.96), accounted for about 10.0% of the total expenditure on anti-infective agents and 7.36% of the total expenditure for the study. Anti-tuberculosis drugs (isoniazid, ethambutol, pyrazinamide and rifampicin) a subclass of anti-infective agents had an aggregate expenditure of NGN 92,345.00 ($570.03). This accounted for about 0.41% of total expenditure on anti-infective agents. The total quantity of anti-tuberculosis drugs used within the study period was 504,950 mg.
Conclusion: The study showed huge expenditure and utilization on cardiovascular and anti-infective drugs within the study area. However, anti-infective drugs were more utilized suggesting that infection is more public goods.
Keywords: Drugutilization ,ca rdiova scu lar,ant i–Infe ctive,com muni typharm acy,pharmacoepidemiology.
Résumé
Contexte : L’étude de l’utilisation des médicaments et des modes de dépenses est un outil important du système de santé. Un vide existe dans de telles recherches en Afrique subsaharienne. Ceci s’agit d’une étude pilote sur les dépenses et les modes d’utilisation des médicaments dans une pharmacie communautaire idéale dans le sud-ouest du Nigéria.
Méthodes : Les données sur les dépenses en médicament (¦ ) et la quantité de médicament (mg) pour les médicaments cardiovasculaires et anti-infectieux ont été obtenues à partir de la base de données électronique de la pharmacie sur une période de vingt-deux mois. Les données analysées au cours de la période comprenaient 63.157 éléments.
Résultats : L’utilisation totale des médicaments, 50,82 kg et les dépenses, ¦ 30.908.084,10 ($190.790,64) pour les cardiovasculaires et anti-infectieux au cours de la période d’étude comprenaient ¦ 22.761.195,88 ($140.501,21) pour les anti- infectieux (73,64%) et les ¦ 8.146.688,22 ($50.289,43) restants pour les médicaments cardiovasculaires (26,36%). L’utilisation des médicaments anti-infectieux était plus élevée, 48,14 kg (94,73%) par rapport aux médicaments cardiovasculaires, 2,68 kg (5,27%) p <0,05. L’utilisation de médicaments antipaludiques 2.253.000 mg à ¦ 2.276.255 ($14.050,96) représentait environ 10,0% des dépenses totales en agents anti-infectieux et 7,36% des dépenses totales pour l’étude. Les médicaments antituberculeux (isoniazide, éthambutol, pyrazinamide et rifampicine), une sous-classe d’agents anti-infectieux ont eu une dépense globale de ¦ 92.345,00 ($570,03). Cela représentait environ 0,41% des dépenses totales en agents anti infectieux. La quantité totale de médicaments antituberculeux utilisés au cours de la période d’étude était de 504.950 mg.
Conclusion : L’étude a montré d’énormes dépenses et utilisation de médicaments cardiovasculaires et anti-infectieux dans l’endroit d’étude. Cependant, les médicaments anti-infectieux étaient plus utilisés, ce qui suggère que l’infection est plus de bien public.
Mots-clés: utilisation de médicament, cardiovasculaire, anti-infectieux, pharmacie communautaire, pharmacoépidémiologie .
Correspondence: Dr. Aduragbenro D.A. Adedapo, Department of Pharmacology and Therapeutics, College of Medicine, University of Ibadan, Ibadan Nigeria. E-mail: debyee1965@yahoo.co.uk
Literaturhinweise
Li P, Zheng Y and Chen X. Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics. Front. Pharmacol. 2017; 8:460. doi: 10.3389/fphar.2017.00460 (Accessed January 6, 2020)
Wettermark B, Persson ME, Wilking N, et al. Forecasting drug expenditure and utilisation patterns in a metropolitan health region. BMC Heal Serv Res. 2010;10(128):4–17.
Hoffman JM, Li E, Doloresco F, et al. Projecting future drug expenditures in U.S. nonfederal hospitals and clinics—2013. Am J Heal Pharm, 2013; 70(6):525–539. doi:102146/ajh120759.
World Health Organisation / WHO International Working Group for Drug Statistics Methodology; WHO Collaborating Centre for Drug Statistics Methodology; WHO Collaborating Centre for Drug Utilisation Research and Clinical Pharmacological Services. Introduction to drug utilisation research. 2003. 6-10 p.
World Health Organization. Methods to analyse medicines in utilisation and expenditure to support pharmaceutical implemetation. Geneva: 2018. Licence CC BY-NC-SA 3.0 IGO
Adedapo ADA, Fawole O, Bamgboye A, et al. Morbidity and mortality patterns of medical admissions in a Nigerian secondary health care hospital. Afr J Med Sci. 2012;41(1):13–20.
National Bureau of Statistics Federal Republic of Nigeria. Annual Abstract of Statistics, 2011. 2011.
WHO Collaborating Centre for Drug Statistics Methodology, ATC classification index with DDDs 2020. Oslo 2009.
The Federal Ministry of Health Abuja Nigeria in collaboration with World Health Organization and European Commission. Essential Medicines List [Internet]. 5th ed. 2010 [cited 2019 Mar 8]. Available from: http://apps.who.int/medicinedocs/documents/s19018en/s19018en.pdf
World Health Organization. WHO Department of Essential Drugs and Medicines., 2014
Sowunmi A. University College Hospital, Ibadan Essential Drugs List and Formulary. 4th revisi. Daybis limited, Ibadan, Nigeria; 2011.
World Health Organisation. Guidelines for the treatment of malaria. 2nd edition. Geneva: 2010.
British National Formulary. 62nd ed. BMJ Group Tavistock Square, London WCIH 9JP,UK; 2011.
British National Formulary. 76th ed. BMJ Group Tavistock Square, London WCIH 9JP,UK; 2019.
Taherian, E., Rao, A., Malemud, C. J., and Askari, A. D. The biological and clinical activity of anti-malarial drugs in autoimmune disorders. Curr. Rheumatol. Rev. 2013; 9, 45–62. doi: 10.2174/1573397111309010010
Mandell GL and Petri WA. Antimicrobial agents (continued) Drugs used in the chemotherapy of tuberculosis, Mycobacterial avium complex disease, and leprosy. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, editors. Goodman’s and Gilman’s The pharmacological basis of Therapeutics. 9th ed. Mc Graw Hill USA; 1996. p. 1155–74. 10.
Beauduy CE, Winston LG. Beta-Lactam & other cell wall-& membrane-active antibiotics. In: Katzung BG, editor. Basic and clinical pharmacology. 14th ed. USA: McGraw-Hill 2018; pg 795-814.
Beauduy CE and Winston LG. Antimycobacterial drugs. In: Katzung BG, editor. Basic and clinical pharmacology. 14th ed. USA: McGraw-Hill 2018 pgs 842-852.
Ankrak D, Hallas J, Odei J et al., A review of the Ghana National health insurance scheme claims database: possibilities and limits of drug utilization research. Basic and Clinical Pharmacology and Therapeutics 2019;124(1): 18-27 https://onlinelbrary,wiley.com/doi/full/10.1111/bcpt.13136
Soyibo A, Olaniyan O and Lawanson AO. National health accounts: Structure, trends and sustainability of health expenditure in Nigeria. African J Econ policy. 2007;14(1):83–109.
OECD. “Health expenditure and financing: Health expenditure indicators”, OECD Health Statistics, 2019 (database), https://doi.org/10.1787/data-00349-en (Accessed on 31 December 2019).